Brain Tumor Protocols / Clinical Studies

For more information on any of the protocols listed below, please contact:

Amar Gajjar, MD
Director of Neuro-Oncology

or

Tabatha Doyle, RN
Coordinator, Brain Tumor Program

(901) 595-2544

Contact us anytime, 24 hours a day, 7 days a week.

 

An Open- Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations.

For: Refractory or refractory solid tumor

 
 

A Phase I Trial of RAD001 (Everolimus) and AVASTIN (Bevacizumab) in Children with Recurrent Solid Tumors

For: Refractory/relapsed solid tumor or brain tumor

 
 

A Phase II Trial of Surgery and fractionated Re-Irradiation for Recurrent Ependymoma

For: recurrent ependymoma

 
 

A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma after Radical Resection

For: Craniopharyngioma

 
 

Phase II Study of Alisertib As A Single Agent in Recurrent or Progressive Central Nervous System Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

For: Recurrent, progressive, or newly diagnosed Atypical Teratoid Rhabdoid Brain Tumors (ATRT)
Solid Tumor : Progressive extra-CNS Malignant Rhabdoid Solid Tumors (MRT)

 
 

Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants with Diffuse Intrinsic Pontine Glioma and High-Grade Glioma

For: Progressive or recurrent pontine glioma or high-grade glioma

 
 

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

For: Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

 
 

Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma

For: Embryonal brain tumors, choroid plexus carcinoma or ependymoma

 

Non St. Jude Protocols

 

A Phase 1 Study of MK-1775 (IND#116495) Concurrent with Local Radiation Therapy For The Treatment Of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas (ADVL1217)

For: Newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

 
 

Phase I/II a, 2-Part, Multi-Cancer, Single-Arm, Open-Label Study to determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to < 18 Years with Advance BRAF V600-Mutation Positive Solid Tumors

For: Solid tumors, giomas, hystiosytosis

 
 

A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Tumor (SCUSF 0901; ACCL0922) Site CTEP ID= TN024

For: Previously treated brain tumors

 
 

A Phase II Randomized Trial of Lenalidomide (NSC#703813, IND#70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas

For: Recurrent, refractory or progressive brain tumors

 
 

Phase II Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors

For: Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma

 
 

Phase III Randomized Trial of Maintenance Chemotherapy Versus Observation in Pediatric Patients (ages 1 to 21 yrs) With Newly Diagnosed Ependymoma Following Induction Chemotherapy and Post-Operative Radiation Therapy

For: Intracranial ependymoma

 
 

Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor

For: Gliomas

 
 

A Phase I /II Study of ABT-888, an Oral Poly (ADP-Ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide (TMZ), in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)

For: newly diagnosed diffuse intrinsic pontine gliomas (DIPG)

 
 

Phase II Study of Peginterferon Alfa-2B (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma

For: Unresectable or recurrent craniopharyngioma

 
 

A Phase I Study of CDK4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors

For: Retinoblastoma Protein 1 (Rb1) Positive Recurrent, Progressive, or Refractory Central Nervous System Tumors

 
 

A Phase II Study of Everolimus for Recurrent or Progressive Low Grade Gliomas in Children

For: Recurrent or progressive low grade gliomas

 
 

A Safety Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E in Children with Recurrent/Refractory BRAFV600E-Mutant Brain Tumors [PNOC-002, CC #120819, IND#116870 (exempt)]

For: Brain Tumors (Recurrent and Refractory)